Phenprocoumon is a synthetic 4-hydroxycoumarin derivative belonging to the vitamin K antagonist class of oral anticoagulants. It is a long-acting anticoagulant active pharmaceutical ingredient used in the development and manufacture of pharmaceutical formulations for the management and prevention of thromboembolic disorders. Phenprocoumon works by interfering with the vitamin K cycle, thereby reducing the synthesis of vitamin K-dependent coagulation factors.
Phenprocoumon is chemically known as 4-hydroxy-3-(1-phenylpropyl)chromen-2-one and has the molecular formula C18H16O3 with a molecular weight of 280.32 g/mol. The API is identified by CAS No. 435-97-2 and belongs to the 4-hydroxycoumarin family of anticoagulant compounds.
Phenprocoumon API is an important pharmaceutical ingredient for formulations where controlled anticoagulant activity is required. As a vitamin K antagonist, its pharmacological action is related to inhibition of vitamin K-dependent coagulation factor production in the liver. This mechanism differentiates Phenprocoumon from direct oral anticoagulants that directly inhibit specific coagulation enzymes.
The relatively long duration of action of Phenprocoumon has historically made it suitable for oral anticoagulant therapy requiring sustained anticoagulant effects. Pharmaceutical formulations containing Phenprocoumon require careful dose control and quality assurance because anticoagulant activity must remain within the intended therapeutic range.
For API manufacturers, consistent chemical identity, chromatographic purity, assay determination and control of process-related impurities are important aspects of Phenprocoumon production. The final quality specification should be established using applicable pharmacopoeial requirements, validated analytical methods and regulatory requirements for the intended market.
Phenprocoumon contains a chromen-2-one core characteristic of 4-hydroxycoumarin anticoagulants, together with a phenylpropyl substituent. Its chemical structure provides the basis for its interaction with the vitamin K-dependent coagulation pathway.
Key chemical information:
Phenprocoumon is primarily associated with pharmaceutical products used for anticoagulant therapy. Its activity is based on disruption of vitamin K recycling, which decreases the availability of active vitamin K required for the synthesis of coagulation factors II, VII, IX and X, as well as regulatory proteins involved in coagulation.
Phenprocoumon API can therefore be used as an active ingredient in the development and manufacture of oral anticoagulant formulations. Pharmaceutical manufacturers require API material with controlled purity and reproducible physicochemical characteristics to support consistent formulation performance.
Because Phenprocoumon has anticoagulant activity, pharmaceutical development requires careful consideration of dosage, formulation characteristics, analytical controls and regulatory requirements. API quality should be supported by appropriate certificates of analysis, validated analytical procedures and stability information.
Quality control is a fundamental part of Phenprocoumon API manufacturing. The identity of the active ingredient should be confirmed using suitable analytical techniques, while assay and related substances should be evaluated using validated chromatographic or other appropriate methods.
Typical quality-control programs may include:
The specific acceptance limits should correspond to the applicable registered specification rather than being replaced with generic API limits.
Phenprocoumon has been investigated using chromatographic analytical techniques, including reversed-phase HPLC. Historical analytical literature describes HPLC determination of Phenprocoumon using UV detection, demonstrating the applicability of chromatographic analysis for quantitative determination.
For modern pharmaceutical quality control, the analytical procedure should be appropriately validated for parameters such as specificity, linearity, accuracy, precision, range, detection limit and quantitation limit where applicable. Related-substance methods should be capable of adequately separating Phenprocoumon from relevant degradation products and process-related impurities.
It is important to distinguish an analytical method from a pharmacopoeial release specification. A published HPLC method or research method should not automatically be represented as an official API assay limit.
Purity control is particularly important for pharmaceutical APIs intended for regulated formulations. Manufacturing processes should be designed to minimize process-related impurities and degradation products. Appropriate purification, crystallization, drying and handling procedures can help achieve reproducible API quality.
Chromatographic impurity profiling can provide information about individual and total related substances. Where applicable, analytical methods should be capable of detecting impurities at suitably low levels in accordance with the relevant regulatory and pharmacopoeial requirements.
For Phenprocoumon, numerical impurity limits should be taken from the applicable current specification or regulatory dossier rather than using unsupported generic limits.
Phenprocoumon is a solid organic compound with a reported melting point in the region of 177–181°C. This physical characteristic can be useful as a supplementary identity or characterization parameter, although melting point should not be substituted for a validated identity test.
The API should be stored and handled under controlled pharmaceutical conditions to minimize exposure to contamination, excessive moisture, heat and other environmental factors that could affect quality.
Phenprocoumon API should be packed in suitable pharmaceutical-grade containers that provide appropriate protection against contamination and environmental exposure. Packaging should be compatible with the API and the intended storage conditions.
Recommended storage conditions should be established according to stability data and the approved product specification. Proper labeling should include product name, batch number, manufacturing information, retest or expiry information where applicable, storage requirements and relevant handling instructions.
For pharmaceutical development and commercial manufacturing, Phenprocoumon API documentation may include a Certificate of Analysis (CoA), specification sheet, analytical method information, safety documentation, batch information and stability data, as applicable.
For regulated markets, API manufacturers should maintain appropriate documentation supporting identity, purity, assay, impurity control, manufacturing consistency and traceability. The final API specification should be aligned with the requirements applicable to the destination market and intended pharmaceutical formulation.
Consistent API quality is essential for pharmaceutical products containing anticoagulant active ingredients. Variations in assay, impurity profile, moisture, residual solvents or physical characteristics can influence formulation development and product consistency.
A well-controlled Phenprocoumon API manufacturing process therefore combines controlled raw materials, validated processing conditions, appropriate purification, analytical testing and documented quality systems. Consistency from batch to batch is particularly important for pharmaceutical development and regulated manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Melting Point | Approximately 177–181°C |